NEW YORK, March 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Globus Medical, Inc. (NYSE: GMED)'s merger with NuVasive, Inc. Under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock. If you are a Globus shareholder, click here to learn more about your rights and options.
Provention Bio, Inc. (NASDAQ: PRVB)'s sale to Sanofi for $25.00 per share in cash. If you are a Provention shareholder, click here to learn more about your rights and options.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)'s merger with MEI Pharma, Inc. Per the merger agreement, pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger. If you are an Infinity shareholder, click here to learn more about your rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
SOURCE Halper Sadeh LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY57422&Transmission_Id=202303301155PR_NEWS_USPR_____NY57422&DateId=20230330)
Share this article